Sign Up for a Free Account
  • Updated 10.09.2023
  • Released 09.06.1993
  • Expires For CME 10.09.2026

Myotonic dystrophy



The myotonic dystrophies are a multisystem, autosomal dominantly inherited, highly variable muscle disease more frequent in adults. So far two distinct entities have been described: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) (PROMM). In this article, the author reviews the clinical features, pathogenesis, and crucial management points of both myotonic dystrophy type 1 and the more recently described myotonic dystrophy type 2. This review has been updated to include the published clinical phenotype characteristics, management aspects, genetic aspects, and pathogenic mechanisms of myotonic dystrophy type 1 and type 2. The author emphasizes both the similarities and differences between the two forms.

Key points

• The myotonic dystrophies are the most common cause of adult-onset muscular dystrophy.

• Myotonic dystrophy type 1 according to age of onset and symptoms is divided into five forms: congenital, childhood, juvenile, adult, and late-onset.

Phenotypes of DM1 and DM2 are similar, but there are some important differences, including the presence or absence of congenital form, muscles primarily affected (distal vs. proximal), involved muscle fiber types (type 1 vs. type 2 fibers), and some associated multisystemic phenotypes.

• There is currently no cure for the myotonic dystrophies but effective management significantly reduces the morbidity and mortality of patients.

• For the enormous understanding of the molecular pathogenesis of myotonic dystrophy type 1 and myotonic dystrophy type 2, these diseases are now called “spliceopathies” and are mediated by a primary disorder of RNA rather than proteins.

• Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies.

• Small molecules, oligonucleotides, and viral vectors for myotonic dystrophy type 1 and myotonic dystrophy type 2 appear to be very close therapy and the near future is an exciting time for clinicians and patients.

Historical note and terminology

Myotonic dystrophies represent a group of dominantly inherited, multisystem (eye, heart, brain, endocrine, gastrointestinal tract, uterus, skin) diseases that share the core features of myotonia, muscle weakness, and early onset cataracts (before 50 years of age). Clinicians considered myotonic dystrophy to be a single disease until 1909 when Steinert and colleagues first clearly described the “classic” form of myotonic dystrophy, which was called Steinert disease (90). The gene defect responsible for myotonic dystrophy described by Steinert was discovered in 1992 and was found to be caused by expansion of a CTG repeat in the 3’ untranslated region of myotonic dystrophy protein kinase gene (DMPK), a gene located on chromosome 19q13.3 (OMIM 605377), encoding a protein kinase (27; 72; 131). After the discovery of this gene defect, DNA testing revealed a group of patients with dominantly inherited myotonia, proximal more than distal weakness, and cataracts; these patients were previously diagnosed as having myotonic dystrophy of Steinert but lacked the gene defect responsible for this disease. Subsequent clinical studies of kindreds with patients having these characteristics led to new diagnostic labels for these patients: myotonic dystrophy type 2 (247), proximal myotonic myopathy (PROMM) (204; 148), or proximal myotonic dystrophy (PDM) (254). Later studies demonstrated that many of the families identified as having myotonic dystrophy type 2, PROMM, or PDM had a single disorder that results from an unstable tetranucleotide CCTG repeat expansion in intron 1 of the nucleic acid-binding protein (CNBP) gene (previously known as zinc finger 9 gene, ZNF9) on chromosome 3q21 (OMIM 116955) (198; 124).

Myotonic dystrophy of Steinert, the classical form of myotonic dystrophy that results from an unstable trinucleotide repeat expansion on chromosome 19q13.3, was termed myotonic dystrophy type 1. Patients with the clinical picture of myotonic dystrophy type 2, PROMM, or PDM who have positive DNA testing for the unstable tetranucleotide repeat expansion on chromosome 3q21 were classified as having myotonic dystrophy type 2. Reliability of DNA testing to establish or to exclude the diagnosis of myotonic dystrophy type 1 and type 2 is close to 100% (259). This chapter focuses on myotonic dystrophy type 1 and myotonic dystrophy type 2. The clinical spectrum for both myotonic dystrophy type 1 and myotonic dystrophy type 2 remains a work in progress in view of the fact that it has been possible to identify these disorders only recently, specifically with DNA testing. At present, much more information is available on the natural history of myotonic dystrophy type 1 than myotonic dystrophy type 2, but knowledge of myotonic dystrophy type 2 will increase at a rapid pace over the next several years.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125